Advertisement

Topics

COSMIX molecular biologicals GmbH Company Profile

20:26 EDT 25th September 2017 | BioPortfolio

COSMIX identifies and improves peptides for applications in healthcare, research, and industry. Peptides are high potential product candidates and well characterized in many applications.
COSMIX’s strong and unique technology platforms enable the generation of innovative, tailored peptide products.

Location

Inhoffenstrasse 7
Braunschweig
D-38124
Germany

Contact

Phone: 49 (0)531-120 86-0
Fax: 49 (0)531-120 86-99
Email: info@cosmix.de


News Articles [1087 Associated News Articles listed on BioPortfolio]

Australia’s TGA consults on naming of biologicals

Australia’s drug regulatory agency, the Therapeutic Goods Administration (TGA), announced on 28 July 2017 that it was opening a consultation on how to name biologicals.

Biosimilar substitution in Europe

In the European Union (EU), decisions on the interchangeability or substitution of biosimilars and originator biologicals are not made by the European Medicines Agency (EMA), but at the national level...

Molecular Devices and Cytena Partner collaborate in single cell printing

Molecular Devices, LLC announced a partnership with Cytena GmbH to launch the CloneSelect™ Single-Cell Printer™ in North America. This system utilizes microfluidics-based technology and real-time ...

Biosimilars in the treatment of inflammatory bowel disease

Inflammatory bowel disease (IBD) is mainly characterized by two chronic, relapsing, immune-mediated inflammatory diseases of the gastrointestinal tract: Crohn’s disease and ulcerative colitis. Appro...

Stada bündelt Vertriebsgesellschaften in Deutschland

FRANKFURT (Dow Jones)--Der Arzneimittelkonzern Stada bündelt seine Geschäftsaktivitäten in Deutschland. Die bisher vier Vertriebsgesellschaften Stadavita GmbH, Stada GmbH, cell pharm GmbH und Stad....

People's Republic of China Approves Proliant Biologicals for the Importation of New Zealand BSA

ANKENY, Iowa and FEILDING, New Zealand, July 17, 2017 /PRNewswire/ -- Following a recent Chinese decision, centered around New Zealand Origin Bovine Material, Proliant Biologicals is now eligible to s...

Original-Research: WILEX AG (von EQUITS GmbH): Kaufen

Original-Research: WILEX AG - von EQUITS GmbH Einstufung von EQUITS GmbH zu WILEX AG Unternehmen: WILEX AG ISIN: DE000A11QVV0 Anlass der Studie: Coverage Aufnahme Empfehlung: Kaufen seit: 19.05.20...

Giant molecular cages made for energy conversion and drug delivery

The porous, 'sponge'-type molecules have an enormous internal surface area. This allows their use as 'molecular flasks' or 'molecular containers' that change the reactivity and properties of encapsula...

PubMed Articles [1674 Associated PubMed Articles listed on BioPortfolio]

Dr. Chi-Ming Chu: Respected founder of molecular virology and pioneer of biologicals in China.

Treatment preferences for biologicals in psoriasis: experienced patients appreciate sustainability.

Treatment satisfaction can be improved by integrating patients' preferences into shared decision-making. We recently investigated patients' preferences for attributes of biologicals, and showed high p...

Combining Therapeutic Drug Monitoring with Biosimilars, a Strategy to Improve the Efficacy of Biologicals for Treating Inflammatory Bowel Diseases at an Affordable Cost.

Biologicals provide a tight disease control but not all patients respond favourably to treatment. Some patients do not respond at all (primary non-responders), while other patients respond initially b...

Potential Issues with the Handling of Biologicals in a Hospital.

Clinical development of biologicals and biosimilars - safety concerns.

Clinical Trials [1350 Associated Clinical Trials listed on BioPortfolio]

Non-inferiority of GSK Biologicals' DTPw-HBV/Hib Compared to Two Formulations of GSK Biologicals' DTPw-HBV/Hib

The purpose of this observer-blind study is to generate immunogenicity data with one formulation of GSK Biologicals' DTPw-HBV/Hib vaccine after the primary vaccination course and to demons...

Study of GSK Biologicals' Pandemic Influenza (H1N1) Candidate Vaccine in Children Aged 10 to Less Than 18 Years

The purpose of this study is to show that vaccination with a single dose of GSK Biologicals' pandemic H1N1 vaccine results in an immune response that meets or exceeds European Medicines Ag...

Study to Evaluate GSK Biologicals' GSK2197870A Vaccine Given as Primary Course in Infants

The purpose of this Phase II study is to evaluate the feasibility of GSK Biologicals' GSK2197870A vaccine co-administered with Wyeth-Lederle's Prevenar™ when given in healthy infants as ...

Bioequivalence Study Comparing Two Test Products With One Reference Product, All Containing 5 mg Yohimbine

- Type: Bioequivalence study in male healthy volunteers, therapeutical indication (erectile disfunction) not studied - Products, dosage, and route of administration: ...

A Safety and Immune Study of 2 Types of GlaxoSmithKline's Varicella Vaccines Given as a 2-doses Course to Healthy Children 12-23 Months of Age.

The purpose of this study is to evaluate the safety and immunogenicity of 2 formulations of GSK Biologicals' varicella vaccines given as a 2-dose course in the second year of life.

Companies [1365 Associated Companies listed on BioPortfolio]

COSMIX molecular biologicals GmbH

COSMIX identifies and improves peptides for applications in healthcare, research, and industry. Peptides are high potential product candidates and well characterized in many applications.COSMIX’s st...

MicroDiscovery GmbH

Based in Berlin, MicroDiscovery GmbH is a leading supplier of bioinformatics solutions in the field of functional genomics. Launched in 2000 as a spin-off from the Max Planck Institute for Molecular G...

Fermentas GmbH

FERMENTAS is a world leader in the discovery, manufacturing and marketing of quality molecular biologicals and providing services to the international research community. As a dynamically evolving bio...

Cosmix

Phage-display based services including custom mouse Fab antibodies

Trait Genetics GmbH

TraitGenetics GmbH is the result of increasing demand for molecular marker analysis in plant breeding and biodiversity research. The company was established in 2000 and started to become operational i...

More Information about "COSMIX molecular biologicals GmbH" on BioPortfolio

We have published hundreds of COSMIX molecular biologicals GmbH news stories on BioPortfolio along with dozens of COSMIX molecular biologicals GmbH Clinical Trials and PubMed Articles about COSMIX molecular biologicals GmbH for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of COSMIX molecular biologicals GmbH Companies in our database. You can also find out about relevant COSMIX molecular biologicals GmbH Drugs and Medications on this site too.

Quick Search
Advertisement
 

Relevant Topic

Healthcare
Health care (or healthcare) is the diagnosis, treatment, and prevention of disease, illness, injury, and other physical and mental impairments in humans. Health care is delivered by practitioners in medicine, chiropractic, dentistry, nursing, pharmacy, a...


Corporate Database Quicklinks



Searches Linking to this Company Record